

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 July 2025 (10.07.2025)



(10) International Publication Number
WO 2025/146469 A1

(51) International Patent Classification:

A61K 31/40 (2006.01) A61P 15/12 (2006.01)
A61P 9/00 (2006.01)

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/EP2025/050074

(22) International Filing Date:

03 January 2025 (03.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/618,239	05 January 2024 (05.01.2024)	US
63/637,469	23 April 2024 (23.04.2024)	US
63/648,489	16 May 2024 (16.05.2024)	US

(71) Applicant: NOEMA PHARMA AG [CH/CH]; Barfusserplatz 3, 4051 Basel (CH).

(72) Inventors: GARIBALDI, George; c/o Noema Pharma AG, Barfusserplatz 3, 4051 Basel (CH). LOMBARDO, Ilise; c/o Noema Pharma AG, Barfusserplatz 3, 4051 Basel (CH). LASSER, Robert; c/o Noema Pharma AG, Barfusserplatz 3, 4051 Basel (CH). GURRELL, Rachel; c/o Noema Pharma AG, Barfusserplatz 3, 4051 Basel (CH).

(74) Agent: ICOSA; 83 avenue Denfert-Rochereau, 75014 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT FOR THE SYMPTOMS OF MENOPAUSE AND PERIMENOPAUSE

(57) Abstract: Provided herein are methods of treating symptoms associated with menopause, perimenopause and/or post-menopause in a subject in need thereof by administering to the subject compositions comprising a triple reuptake inhibitor (e.g., Compound 1).

WO 2025/146469 A1